SHIEF (Shield Therapeutics) OCF Margin %: -5.80% (As of Dec. 2025)


What is Shield Therapeutics OCF Margin %?

Shield Therapeutics SHIEF OCF Margin % is -5.80% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 959 Drug Manufacturers companies, Shield Therapeutics ranks worse than 79.77% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Shield Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was $-1.64 Mil. Shield Therapeutics's Revenue for the six months ended in Dec. 2025 was $28.25 Mil. Therefore, Shield Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was -5.80%.

As of today, Shield Therapeutics's current OCF Yield % is -3.61%.

The historical rank and industry rank for Shield Therapeutics's OCF Margin % or its related term are showing as below:

SHIEF' s OCF Margin % Range Over the Past 10 Years
Min: -3378.67   Med: -347.27   Max: 1.28
Current: -6.8

During the past 12 years, the highest OCF Margin % of Shield Therapeutics was 1.28%. The lowest was -3378.67%. And the median was -347.27%.

SHIEF's OCF Margin % is ranked worse than
79.77% of 959 companies
in the Drug Manufacturers industry
Industry Median: 9.94 vs SHIEF: -6.80

Shield Therapeutics OCF Margin % Related Terms

Shield Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics OCF Margin % Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,202.29 -410.82 -283.73 -21.04 -6.80

Shield Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -184.44 -29.39 -15.99 -8.12 -5.80

SHIEF vs ZTS, UTHR, VTRS: OCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics OCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's OCF Margin % falls into.


Shield Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Shield Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.38/49.701
=-6.80 %

Shield Therapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.638/28.254
=-5.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -5.80% mean?
Shield Therapeutics (SHIEF) has a OCF Margin % of -5.80% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Shield Therapeutics and its competitors. According to the industry distribution chart, Shield Therapeutics ranks #765 out of 959 companies in the Drug Manufacturers industry, placing it in the top 79.8%.
Is Shield Therapeutics' OCF Margin % too high?
Shield Therapeutics' current OCF Margin % is -5.80%. Based on the distribution chart, Shield Therapeutics ranks #765 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Shield Therapeutics' OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #765 out of 959 companies for OCF Margin %. This places Shield Therapeutics in the lower half of its industry. The industry median OCF Margin % is 9.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current OCF Margin % is -5.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (SHIEF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.13, compared to a current price of $0.08 — trading 38.5% below its estimated fair value. The current OCF Margin % is -5.80%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Shield Therapeutics (SHIEF), the current OCF Margin % is -5.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges STX:UK1JS:Germany
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.